

Client
Gurugram
Pathkind Diagnostics Pvt. Ltd.
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

Processed By
Pathkind Diagnostics Pvt. Ltd.
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

Name	: Mr. FC06	Billing Date	: 07/07/2023 12:22:45
Age	: 35 Yrs	Sample Collected on	: 10/07/2023 10:01:31
Sex	: Male	Sample Received on	: 10/07/2023 11:02:13
P. ID No.	: P1000100012751	Report Released on	: 14/07/2023 15:52:15
Accession No	: 10002304807	Barcode No.	: 10002304807-01
Referring Doctor	: Self	Ref no.	:
Referred By	:		

Report Status - Final

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

HAEMATOLOGY

HLA B27, Flowcytometry Sample: EDTA Blood Method: Flowcytometry	Negative	Negative
------------------------------------------------------------------------------	----------	----------

HLA B27, Flowcytometry

Clinical Significance

HLA-B27 is a major histocompatibility complex (MHC) class I molecule. MHC class I molecules are cell-surface glycoproteins that are expressed on most nucleated human cells and platelets. The presence of HLA-B27 antigen is strongly associated with ankylosing spondylitis (AS), a chronic inflammatory disease of the axial musculoskeletal system and a few other rheumatic disorders (Reiter's syndrome, acute anterior uveitis, and inflammatory bowel disease). HLA-B27 testing is routinely used to screen for AS since 90% of patients with AS have the HLA-B27 surface antigen compared to only 8% of healthy individuals. The Anti-HLA- B27 antibody has been shown to cross-react, most commonly with HLA-B7. The Log mean fluorescence (LMF) for some cross-reacting samples can fall on the positive side of the decision marker, thus resulting in false-positive results. Results falling in dual positive or weak positive are reported as indeterminate and needs to be confirmed by an alternate method.

** End of Report**


Dr. Aarti Khanna Nagpal
DNB (Pathology)
Senior Consultant

